Last Updated: September 25, 2026

Details for Patent: 8,168,793


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 8,168,793 protect, and when does it expire?

Patent 8,168,793 protects ONGENTYS and is included in one NDA.

This patent has forty-two patent family members in twenty-seven countries.

Summary for Patent: 8,168,793
Title:Nitrocatechol derivatives as COMT inhibitors
Abstract:New compounds of formula I are described. The compounds have potentially valuable pharmaceutical properties in the treatment of some central and peripheral nervous system disorders.
Inventor(s):David Alexander Learmonth, Laszlo Erno Kiss, Pedro Nuno Leal Palma, Humberto Dos Santos Ferreira, Patricio Manuel Vieira Araújo Soares da Silva
Assignee: Bial Portela and Cia SA
Application Number:US11/989,447
Patent Claim Types:
see list of patent claims
Use; Composition;

Drugs Protected by US Patent 8,168,793

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Amneal ONGENTYS opicapone CAPSULE;ORAL 212489-001 Apr 24, 2020 RX Yes No ⤷  Start Trial ⤷  Start Trial Y Y ADJUNCTIVE TREATMENT TO LEVODOPA/CARBIDOPA IN PATIENTS WITH PARKINSON’S DISEASE EXPERIENCING OFF EPISODES ⤷  Start Trial
Amneal ONGENTYS opicapone CAPSULE;ORAL 212489-002 Apr 24, 2020 RX Yes Yes ⤷  Start Trial ⤷  Start Trial Y Y ADJUNCTIVE TREATMENT TO LEVODOPA/CARBIDOPA IN PATIENTS WITH PARKINSON’S DISEASE EXPERIENCING OFF EPISODES ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,168,793

PCT Information
PCT FiledJuly 26, 2006PCT Application Number:PCT/PT2006/000020
PCT Publication Date:February 01, 2007PCT Publication Number: WO2007/013830

International Family Members for US Patent 8,168,793

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office 1907382 ⤷  Start Trial 300848 Netherlands ⤷  Start Trial
European Patent Office 1907382 ⤷  Start Trial 122016000095 Germany ⤷  Start Trial
European Patent Office 1907382 ⤷  Start Trial PA2016036 Lithuania ⤷  Start Trial
European Patent Office 1907382 ⤷  Start Trial CA 2016 00061 Denmark ⤷  Start Trial
European Patent Office 1907382 ⤷  Start Trial 93327 Luxembourg ⤷  Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.